Superior Tolerability of Altered Dosing Schedule of Sunitinib with 2-Weeks-on and 1-Week-off in Patients with Metastatic Renal Cell Carcinoma--Comparison to Standard Dosing Schedule of 4-Weeks-on and 2-Weeks-off
نویسندگان
چکیده
منابع مشابه
RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial.
BACKGROUND The standard sunitinib schedule, 4 weeks on, followed by 2 weeks off (4/2 schedule), is associated with troublesome toxicities, and maintenance of adequate sunitinib dosing and drug levels, which are essential for achieving an optimal treatment outcome, is challenging. The objective of this study was to investigate the efficacy and safety of an alternative sunitinib dosing schedule o...
متن کاملSunitinib dosing schedule 2/1 improves tolerability, efficacy, and health-related quality of life in Chinese patients with metastatic renal cell carcinoma.
PURPOSE To assess the efficacy and tolerability of sunitinib dosing schedule of 2 weeks on and 1 week off (schedule 2/1) vs. the traditional schedule of 4 weeks on and 2 week off (schedule 4/2) and its influence on health-related quality of life (HRQoL) in Chinese patients with metastatic renal cell carcinoma (mRCC). MATERIALS AND METHODS A retrospective analysis of 108 patients with mRCC who...
متن کاملa comparison of teachers and supervisors, with respect to teacher efficacy and reflection
supervisors play an undeniable role in training teachers, before starting their professional experience by preparing them, at the initial years of their teaching by checking their work within the proper framework, and later on during their teaching by assessing their progress. but surprisingly, exploring their attributes, professional demands, and qualifications has remained a neglected theme i...
15 صفحه اولPrognostic relevance of sunitinib toxicities and comparison of continuous vs. intermittent sunitinib dosing schedule in metastatic renal cell cancer patients
AIM OF THE STUDY Sunitinib-related side effects may develop as a result of the pharmacokinetic pathway affects the of the drug. MATERIAL AND METHODS Data on mRCC patients were obtained from the hospital archives. Outcomes of patients were evaluated in terms of related prognostic factors, sunitinib adverse events during the treatment, and two different sunitinib dosing schedules. RESULTS Sev...
متن کاملContinuous or intermittent? On the dosing schedule of sunitinib for advanced renal cell carcinoma
Sunitinib is globally approved for treatment of advanced renal cell carcinoma (RCC) at a dosage of 50 mg/day with four weeks on treatment and two weeks off, based on a randomized phase III trial in which its superiority over interferon alpha was established as first-line therapy for patients with metastatic RCC (1). On the other hand, continuous daily dosing of sunitinib at a dosage of 37.5 mg/...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Japanese Journal of Clinical Oncology
سال: 2014
ISSN: 0368-2811,1465-3621
DOI: 10.1093/jjco/hyt232